Generic Name and Formulations:
C1 esterase inhibitor (recombinant) 2100 IU; per vial; lyophilized pwd for IV inj after reconstitution; preservative-free.
Valeant Pharmaceuticals, Inc
Indications for RUCONEST:
Treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).
Limitations Of use:
Efficacy not established in hereditary angioedema (HAE) patients with laryngeal attacks.
Give by slow IV inj over 5 mins. <84kg: 50 IU/kg. ≥84kg: 4200 IU. Max 4200 IU/dose. May give second dose if attack symptoms persist; max 2 doses/24hrs.
Allergy to rabbits or rabbit-derived products.
Discontinue if hypersensitivity reactions occur. Monitor patients with known risk factors for thrombotic events (eg, indwelling venous catheter, history of thrombosis, atherosclerosis, morbid obesity, immobility). Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Risk of thrombotic events with concomitant oral contraceptives or certain androgens.
Headache, nausea, diarrhea; thrombotic events, hypersensitivity reactions (may be severe).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy